Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Dr Reddy’s Laboratories ( (RDY) ) just unveiled an update.
On June 30, 2025, Dr. Reddy’s Laboratories released its Business Responsibility and Sustainability Report (BRSR) for the financial year 2024-25. This report, which is part of the company’s Integrated Annual Report, highlights the company’s commitment to sustainability and responsible business practices. The BRSR is available on the company’s website, indicating Dr. Reddy’s ongoing efforts to maintain transparency and accountability in its operations, which is crucial for its stakeholders and industry positioning.
The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories’ strong financial performance is the most significant factor, underscored by consistent revenue growth and profitability. Technical analysis supports a favorable stock trend, although valuation is fair with modest income potential. The absence of earnings call and corporate events data did not impact the overall score.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company focuses on providing affordable and innovative medicines to patients worldwide, with a significant presence in both generic and branded formulations.
Average Trading Volume: 2,030,559
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.7B
See more data about RDY stock on TipRanks’ Stock Analysis page.